NRD
KRYS icon

Nebula Research & Development’s Krystal Biotech KRYS Stock Holding History

Nebula Research & Development’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,355
Closed -$324K – 471
2025
Q2 		$324K Sell
2,355
-3,865
-62% -$568K 0.03% 768
2025
Q1 		$1.12M Buy
6,220
+3,550
+133% +$597K 0.1% 337
2024
Q4 		$418K Sell
2,670
-2,035
-43% -$361K 0.05% 617
2024
Q3 		$856K Buy
4,705
+3,513
+295% +$677K 0.1% 354
2024
Q2 		$219K Buy
+1,192
New +$200K 0.04% 704
2023
Q3 		– Sell
-5,325
Closed -$625K – 577
2023
Q2 		$625K Buy
+5,325
New +$544K 0.47% 74

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Nebula Research & Development's KRYS Position: Q3 2025 in Review

Nebula Research & Development sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 2,355 shares — an estimated $324K sold.

Nebula Research & Development first reported a position in KRYS in Q2 2023 and held it in 6 quarters. The position peaked at $1.12M in Q1 2025. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • Nebula Research & Development reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 2,355 Krystal Biotech shares in Q3 2025, an estimated $324K.
  • Nebula Research & Development first reported a position in Krystal Biotech in Q2 2023 and held it in 6 quarters.
  • Nebula Research & Development's Krystal Biotech position peaked at $1.12M in Q1 2025.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.